(E)-3-(3-oxobut-1-enyl)benzaldehyde | 146982-55-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(3-oxobut-1-enyl)benzaldehyde
• 英文别名: (E)-3-(3-oxobut-1-en-1-yl)benzaldehyde；3-[(E)-3-oxobut-1-enyl]benzaldehyde
• CAS: 146982-55-0
• 化学式: C₁₁H₁₀O₂
• 分子量: 174.199
• InChiKey: CFDCSMWGWWZMKS-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  间苯二甲醛 、 二丙酮醇 在 chloro[1,3-bis(2,6-di-i-propylphenyl)imidazol-2-ylidene]copper(I) 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以63%的产率得到(E)-3-(3-oxobut-1-enyl)benzaldehyde
  参考文献：
  名称：

  铜催化β-羟基酮或腈与醛的逆醛醇缩合反应：化学和立体选择进入（E）-烯酮和（E）-丙烯腈†

  摘要：

  报道了铜催化的β-羟基酮或腈与醛的转移醇醛式反应，这使得化学和立体选择性地接近（E）-α，β-不饱和酮和（E）-丙烯腈。建议原位铜（I）促进β-羟基酮或腈的逆向羟醛缩合反应的关键步骤，以生成反应性铜（I）烯醇盐或氰甲基中间体，随后发生醛缩醛与醛缩合以生成产物。该反应在6.0 mol％NaO t存在下，使用1.2 mol％Cu（IPr）Cl（IPr表示1,3-双（2,6-二异丙基苯基）咪唑-2-亚烷基）作为催化剂Bu助催化剂在室温或70°C下。一系列的芳基和杂芳基醛以及丙烯醛与可耐受的许多有用的官能团相容。在温和的弱碱性条件下，苯甲醛的竞争性Cannizzaro型反应和碱敏感官能团的副反应可以得到有效抑制，与经典的羟醛反应相比，该反应具有合成优势。该反应的合成潜力通过具有极高收率（高达91％）的生物活性喹啉和1,8-萘啶的一步合成得到了进一步证明。最后，在逆醛醇/醛醇两阶段机理的背景下，使用

  DOI：

  10.1039/c6ob01198e

文献信息

• Design, green synthesis, antioxidant activity screening, and evaluation of protective effect on cerebral ischemia reperfusion injury of novel monoenone monocarbonyl curcumin analogs
  作者：Wenfei He、Jingsong Wang、Qiling Jin、Jiafeng Zhang、Yugang Liu、Zewu Jin、Hua Wang、Linya Hu、Lu Zhu、Mengya Shen、Lili Huang、Shengwei Huang、Wulan Li、Qichuan Zhuge、Jianzhang Wu

  DOI：10.1016/j.bioorg.2021.105080

  日期：2021.9

  of overcoming the instability and pharmacokinetic defects of curcumin possess notable antioxidant activity but are found to be significantly toxic. In this study, a novel skeleton of the monoenone monocarbonyl curcumin analogue sAc possessing reduced toxicity and improved stability was designed on the basis of the DMCA skeleton. Moreover, 32 sAc analogs were obtained by applying a green, simple, and

  高效低毒的抗氧化剂具有治疗脑缺血再灌注损伤（CIRI）的潜力。二烯酮单羰基姜黄素类似物 (DMCA) 能够克服姜黄素的不稳定性和药代动力学缺陷，具有显着的抗氧化活性，但被发现具有显着毒性。在这项研究中，基于 DMCA 骨架设计了一种具有降低毒性和提高稳定性的单烯酮单羰基姜黄素类似物 sAc 的新型骨架。此外，通过应用绿色、简单、经济的合成方法，获得了 32 种 sAc 类似物。使用 H 2 O 2筛选在 PC12 细胞中具有抗氧化保护作用的多种 sAc 类似物诱导氧化应激损伤模型， 通过随机森林算法（RF）建立回归系数为R 2 = 0.918921的构效关系（QSAR）定量评价模型。在这些化合物中，最佳活性化合物sAc15通过激活 Nrf2/HO-1 抗氧化信号通路，有效消除响应氧化应激损伤的 ROS 生成，从而对 PC12 细胞的细胞生长产生有效的保护作用。此外，sAc15在小鼠大脑中动脉闭塞
• Histone Deacetylases Inhibitors
  申请人：Minucci Saverio

  公开号：US20080096889A1

  公开（公告）日：2008-04-24

  New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R 1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R 3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.

  本文描述了具有抗肿瘤活性的组蛋白去乙酰化酶新抑制剂及其制备过程。这些化合物属于结构式(I)，其中R1是一个含有至少两个共轭双键的线性或支链，A是一个可选取代的苯基或吡啶基环，Ar是芳基或杂环基团，而R3是氢或烷氧基烷基。该申请还描述了这些化合物在治疗与组蛋白去乙酰化酶活性失调相关的疾病，如肿瘤方面的应用，以及用于给需要该治疗的患者的相关药物组成部分。
• NEW HISTONE DEACETYLASES INHIBITORS
  申请人：MINUCCI Saverio

  公开号：US20100240660A1

  公开（公告）日：2010-09-23

  New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R 1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R 3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.

  本文描述了具有抗肿瘤活性的新型组蛋白去乙酰化酶抑制剂及其制备方法。这些化合物属于结构式（I），其中R1是含有至少两个共轭双键的线性或支链，A是可选取代的苯基或吡啶基环，Ar是芳基或杂环芳基基团，R3是氢或烷氧基烷基。该申请还描述了在治疗与组蛋白去乙酰化酶活性失调相关的疾病，如肿瘤方面使用这些化合物的方法，以及适用于需要该治疗的患者的相关药物组合物。
• Preparation of monometallic (Pd, Ag) and bimetallic (Pd/Ag, Pd/Ni, Pd/Cu) nanoparticles via reversed micelles and their use in the Heck reaction
  作者：Felora Heshmatpour、Reza Abazari、Saeed Balalaie

  DOI：10.1016/j.tet.2012.02.028

  日期：2012.4

  The metal nanoparticles (NPs) have been prepared using a water-in-oil microemulsion system of water/dioctyl sulfosuccinate sodium salt (aerosol-OT, AOT)/isooctane at 25 degrees C. Since the NPs produced in this system can endure forcing conditions (100 degrees C), this system has been used for the synthesis of nano-catalysts in the Heck reactions. FE-SEM, DLS, and UV/vis analyses have been used to characterize the surface morphology, size, and proof of the formation of all the prepared metal NPs, respectively. In addition, the effects of some reaction parameters (here, bases and solvents) were optimized. Differences in the catalytic properties of the synthesized NPs have also been investigated. Consequently, the Pd/Cu (4:1) bimetallic NP showed the highest activity in the C-C coupling reaction of the iodobenzene with the styrene, thus it is employed as the superior catalyst in this study. Therefore, the Pd/Cu (4:1) bimetallic NPs were further investigated using TEM and XRD analyses. This catalyst system is also reusable for six runs with very negligible reduction in the efficiency. (C) 2012 Elsevier Ltd. All rights reserved.
• PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Mitobridge, Inc.

  公开号：US20170304255A1

  公开（公告）日：2017-10-26

  Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).